A carregar...
Publicação
Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 809.84 KB | Adobe PDF |
Orientador(es)
Resumo(s)
The 2024/25 influenza season in Europe is currently characterised by the co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness estimates from eight European studies conducted in 17 countries indicate an overall influenza A vaccine effectiveness of 32–53% in primary care settings and 33–56% in hospital settings, with some indications of lower effectiveness by subtype and higher effectiveness against influenza B (≥58% across settings). Where feasible, influenza vaccination should be encouraged and other preventive measures strengthened.
Descrição
Palavras-chave
Influenza Vaccine Effectiveness 2024-2025 Europe Determinantes da Saúde e da Doença Infecções Respiratórias
Contexto Educativo
Citação
Euro Surveill. 2025 Feb;30(7):2500102. doi: 10.2807/1560-7917.ES.2025.30.7.2500102. Erratum in: Euro Surveill. 2025 Mar;30(11). doi: 10.2807/1560-7917.ES.2025.30.11.240320c
Editora
European Centre for Disease Prevention and Control